A second attempt to combine Truvada and Sustiva into a single HIV pill has failed, says Gilead Sciences. The failure will delay an application to the FDA until sometime next year, said Gilead, which saw its shares slide on the news this morning. A spokesperson for Gilead said that researchers plan to employ new technology in mixing the drugs in the next round. Gilead earns about $1.33 billion a year from the sale of HIV drugs.
- read this story from the Los Angeles Times for more